In summary, our findings indicate that Panobinostat may serve as a promising therapeutic strategy for prostate cancer by inhibiting HDAC3, enhancing H3K27 acetylation in the LHPP promoter region to augment its transcription, and stabilizing LHPP protein through the modulation of its acetylation and ubiquitination. Here, HDAC3 is linked to Familial prostate cancer.